Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL400027 | 1.00 | GAA (0.51) | GAANOS3NOS2CHRM1L3MBTL1 | |
| SCHEMBL9790042 | 1.00 | GAA (0.51) | GAANOS3NOS2CHRM1L3MBTL1 | |
| SCHEMBL9790049 | 1.00 | GAA (0.51) | GAANOS3NOS2CHRM1L3MBTL1 | |
| SCHEMBL595031 | 1.00 | GAA (0.51) | GAANOS3NOS2CHRM1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL4762541 | 0.98 | GAA (0.50) | GAANOS3NOS2CHRM1L3MBTL1 | |
| SCHEMBL403641 | 0.88 | GAA (0.51) | GAANOS3NOS2CHRM1L3MBTL1 | |
| SCHEMBL9721727 | 0.88 | GAA (0.51) | GAANOS3NOS2CHRM1L3MBTL1 | |
| SCHEMBL405104 | 0.88 | GAA (0.51) | GAANOS3NOS2CHRM1L3MBTL1 | |
| SCHEMBL20599062 | 0.87 | SMN1; SMN2 (0.47) | GAANOS3NOS2CHRM1L3MBTL1 | |
| SCHEMBL30863789 | 0.85 | CHRNB2 (0.40) | GAATSHRPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843552-A | Resolution method of cis-4-amino-3-methoxypiperidine-1-formate optical isomer | 中国医学科学院药物研究所 | 2024-04-09 | — | — | CN | disclosed |
| US-8114880-B2 | Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid MTP inhibiting compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-14 | — | — | US | disclosed |
| EP-2076494-B1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-28 | — | — | EP | disclosed |
| US-20090325980-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-31 | — | — | US | disclosed |
| EP-2076494-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008049806-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-02 | — | — | WO | disclosed |
| EP-0934272-B1 | Process for preparing an intermediate useful in the synthesis of cisapride | JANSSEN PHARMACEUTICA NV (BE) | 2002-07-24 | — | — | EP | disclosed |
| US-6218542-B1 | CONVERTING 1-(3-(4-FLUOROPHENOXY)-PROPYL)-3-METHOXY-4-PIPERIDINAMINE HAVING A CIS/TRANS RATIO OF ABOUT 93/7 INTO ITS ACID ADDITION SALT, BY TREATMENT WITH HCL OR HNO3 IN ISOPROPANOL, N-BUTANOL, | JENSSEN PHARMACEUTICA N.V. (BE) | 2001-04-17 | — | — | US | disclosed |
| EP-0640601-B1 | BENZAMIDE DERIVATIVE | HOKURIKU PHARMACEUTICAL (JP) | 1996-12-04 | — | — | EP | disclosed |
| US-5500422-A | FOR TREATING GASTROINTESTINAL DISEASES | HOKURIKU SEIYAKU CO. LTD. (JP) | 1996-03-19 | — | — | US | disclosed |
| US-5395832-A | Gastrointestinal disorders | HOKURIKU SEIYAKU CO., LTD. (JP) | 1995-03-07 | — | — | US | disclosed |
| EP-0640601-A1 | BENZAMIDE DERIVATIVE | HOKURIKU SEIYAKU CO., LTD. (JP) | 1995-03-01 | — | — | EP | disclosed |
| US-5137896-A | Useful in treatment of gastrointestinal and psychic disorder; analgesic, antiemetic and antiulcer agent | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-08-11 | — | — | US | disclosed |
| US-5057525-A | Stimulators of gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-10-15 | — | — | US | disclosed |
| US-4990521-A | Treating diarhea | JANSSEN PHARMACEUTICA (BE) | 1991-02-05 | — | — | US | disclosed |
| US-4962115-A | Stimulate motility of gastrointestinal system | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-10-09 | — | — | US | disclosed |
| EP-0251417-A2 | 4-(aroylamino) piperidinebutanamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-01-07 | — | — | EP | disclosed |
| EP-0076530-B1 | NOVEL N-(3-HYDROXY-4-PIPERIDINYL)BENZAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-12-11 | — | — | EP | disclosed |
| EP-0076530-A2 | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325980-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | PNLIP, APOB, LIPC | GAA 352/4885NOS3 2746/4885NOS2 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.